Rameda Pharmaceuticals
Mahmoud Fayek, CFA, is an experienced finance professional currently serving as Chief Financial Officer and Chief Operating Officer at Rameda Pharmaceuticals since May 2019. Previously, Mahmoud held various roles at Compass Capital for Financial Investments from July 2010 to April 2019, including Vice President of Private Equity, where responsibilities included leading investment processing and due diligence, managing client portfolios, and automating business processes. Mahmoud also served as Corporate Finance Analyst at Fayek Decorative Furniture S.A.E. from February 2009 to June 2010, where achievements included improving cash flow management and securing significant contracts. Mahmoud holds a B.A. in Finance from the Arab Academy for Science, Technology and Maritime Transport and completed studies at the CFA Institute from 2010 to 2012.
Rameda Pharmaceuticals
Our Vision: To become the most valuable emerging pharmaceutical company in Egypt. Our Mission: To provide our customers quality health care solutions in a cost effective manner by developing products and services that satisfy their health requirements. Establishment Rameda began operations in 1994 and was established by a group of Gulf investors with the intention of creating one of the largest pharmaceutical operations in the region. Owners hired V-Konsult of Germany to create a state-of-the art design. Contracted British Carter Construction company to build the Rameda’s facilities. Partnership with Alcon In 1999, Rameda entered into an agreement with Alcon to manufacture – under license - their ophthalmology products. In order to guarantee the quality of their products, Alcon built one of the highest quality eye production facilities in the region at Rameda. Quality enhancement Rameda renewed the syrup production to become GMP (Good Manufacturing Practice). A new Beginning In 2011, Compass Capital led a consortium of private equity investors for the acquisition of 100% of Rameda. Compass Capital plans to establish Rameda as a regional leader in the industry. To execute this strategy Rameda hired a new management team with a proven track record to complement the existing team. Company has commissioned M+W Group to transform solid dosage and beta lactam areas into GMP. Brining entire facility to compliance.